Amgen and Japanese drugmaker Eisai joined the trial, which enrolled its first patient Oct. 26. Both drugmakers’ experimental COVID-19 therapies are being evaluated by reinforcement learning, a type of AI that can adjust treatment protocols based on data revealing how each patient responds to the novel drugs.
The reinforcement learning approach allows critical questions to be addressed with real-time data rather than letting time pass until a specified sample size is achieved. The trial design also improves the likelihood that participants could benefit from the treatments they’re receiving.
Amgen’s apremilast and Eisai’s eritoran, both inflammation suppressors, are being tested in the trial.
More articles on artificial intelligence:
CMS to pay physicians to use stroke, diabetes complication detection algorithms
6 recent studies exploring AI in healthcare
Houston Methodist develops AI-powered breast cancer risk calculator
